This study discusses the relationship between Polycystic Ovary Syndrome (PCOS) and diabetes in women, which has become increasingly prevalent due to changing lifestyles and environmental factors. The characteristic that distinguishes women with PCOS is hyperandrogenism which results from abnormal ovarian or adrenal function, which leads to the overproduction of androgens. Excessive androgens in women increase the risk of Type 2 diabetes (T2D) and insulin resistance (IR). Nowadays, diabetes affects people of all ages and is linked to factors such as lifestyle, genetics, stress, and aging. Diabetes, the uncontrolled high blood sugar level can potentially harm kidneys, nerves, eyes, and other organs and there is no cure, making it a concerning disease in developing nations. This research tried to submit the evidence through feature-wise correlation analyses between PCOS and diabetes. Hence, this model utilized the Exploratory Data Analysis (EDA) and the Elbow clustering algorithms for the experimental purpose in which the EDA deeply analyzed the features of PCOS and diabetes and recorded a positive correlation of 95%. The Elbow clustering technique is employed for verifying the correlations identified through EDA. Although limited research exists on this specific disease, this work provides potential evidence for the research community by evaluating the clustering results using Silhouette Score, Calinski-Harabasz Index, and Davies-Bouldin Index.

Download full-text PDF

Source
http://dx.doi.org/10.1080/10255842.2023.2252957DOI Listing

Publication Analysis

Top Keywords

pcos diabetes
12
polycystic ovary
8
ovary syndrome
8
elbow clustering
8
diabetes
6
analysis risk
4
risk factors
4
factors diabetics
4
diabetics polycystic
4
women
4

Similar Publications

: Rat sarcoma (Ras) proteins, Kirsten, Harvey, and Neuroblastoma rat sarcoma viral oncogene homolog (KRAS, HRAS, and NRAS, respectively), are a family of GTPases, which are key regulators of cellular growth, differentiation, and apoptosis through signal transduction pathways modulated by growth factors that have been recognized to be dysregulated in PCOS. This study explores Ras signaling proteins and growth factor-related proteins in polycystic ovary syndrome (PCOS). : In a well-validated PCOS database of 147 PCOS and 97 control women, plasma was batch analyzed using Somascan proteomic analysis for circulating KRas, Ras GTPase-activating protein-1 (RASA1), and 45 growth factor-related proteins.

View Article and Find Full Text PDF

Endocrine and metabolic effects of GLP-1 receptor agonists on women with PCOS, a narrative review.

Endocr Connect

March 2025

K Gariani, Division of Endocrinology, Diabetes, Nutrition and Therapeutic Patient Education, Department of Medical Specialties, Geneva University Hospitals, Geneva, Switzerland.

Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age. This condition is associated with various hormonal, reproductive, and metabolic alterations, including androgen excess, ovulatory disorders, and a hyperinsulinemic state. A personalized therapeutic approach is necessary to improve PCOS, focusing on patient's main concerns, with the goal of addressing ovarian dysfunction, reducing hyperandrogenism, and improving metabolic alterations, particularly through weight reduction.

View Article and Find Full Text PDF

Background: Metabolic-bariatric surgery (MBS) is the last effective way to lose weight whom around half of the patients are women of reproductive age. It is recommended an interval of 12 months between surgery and pregnancy to optimize weight loss and nutritional status. Predicting pregnancy up to 12 months after MBS is important for evaluating reproductive health services in bariatric centers; therefore, this study aimed to present a prediction model for pregnancy at the first year following MBS using machine learning (ML) algorithms.

View Article and Find Full Text PDF

Glucagon-like peptide 1 (GLP-1), an incretin hormone primarily secreted by L-cells in the gut, prompts insulin release, thus reducing blood sugar levels and causing weight loss by inducing feelings of fullness while curbing appetite. GLP-1 receptor agonists (GLP-1 RAs) mimic its effects, proving highly effective in managing type 2 diabetes mellitus (T2DM) and facilitating weight loss. While predominantly approved for T2DM and obesity, GLP-1 RAs also hold promise for treating other conditions like heart and kidney disease, with ongoing research exploring additional therapeutic applications.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!